TRUMBULL, Conn. and NEW YORK, October 19, 2020 – CooperSurgical and NYU Langone Fertility Center (NYULFC), part of The Prelude Network, announced today independent study results demonstrating increased ongoing pregnancy and live birth rates associated with the use of CooperSurgical’s PGTai 2.0 technology to screen embryos for in vitro fertilization (IVF).[i] This single-center study was conducted by NYULFC; and results were presented today at the American Society of Reproductive Medicine (ASRM) Virtual Scientific Congress.
Preimplantation Genetic Testing for aneuploidy (PGT-A) is performed on embryos produced through IVF; it provides genetic information to help identify embryos that are more likely to result in a successful pregnancy. PGTai 2.0 is an advancement in PGT-A testing that utilizes artificial intelligence to increase objectivity of this screening process.
‘This research moves us an important step closer to our goal of increased live births, improved pregnancy outcomes and further reduction of multiples in pregnancy through greater confidence in single embryo transfer,’ said James A. Grifo, M.D., Ph.D., Director, NYU Langone Fertility Center.
An estimated 48.5 million couples – approximately 15% of couples — are affected by infertility worldwide.[ii] 80,000 babies were born with IVF in 2017 in the United States[iii] and more than one million babies were born in the period 1987 to 2015 in the United States as a result of IVF.[iv]
‘The study is a demonstration of CooperSurgical’s commitment to developing the most advanced technology in the field of genetic testing to advance reproductive medicine and help families,’ said Tony Gordon, Vice President of Business Development, CooperGenomics. ‘By applying artificial intelligence in the PGTaism 2.0 technology, we leverage mathematical algorithms derived from real-world data to achieve objective embryo assessment.’